{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:56:06Z","timestamp":1793393766389,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-77210-2","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T09:20:06Z","timestamp":1730107206000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Patient-reported outcomes of chimeric antigen receptor T-cell therapy in hematologic malignancies: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"14","author":[{"given":"Hyo Jung","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunsuk","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon Woo","family":"Yim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"key":"77210_CR1","doi-asserted-by":"publisher","first-page":"13991","DOI":"10.18632\/oncotarget.24179","volume":"9","author":"D Xu","year":"2018","unstructured":"Xu, D. et al. The development of CAR design for tumor CAR-T cell therapy. Oncotarget. 9, 13991\u201314004 (2018).","journal-title":"Oncotarget"},{"key":"77210_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.56875\/2589-0646.1035","volume":"15","author":"D Yi","year":"2022","unstructured":"Yi, D. et al. Next-generation chimeric Antigen receptor T-cells. Hematol. Oncol. Stem Cell. Ther. 15, 117\u2013121 (2022).","journal-title":"Hematol. Oncol. Stem Cell. Ther."},{"key":"77210_CR3","doi-asserted-by":"publisher","unstructured":"Choi, G., Shin, G. & Bae, S. Price and prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell therapy. Int. J. Environ. Res. Public. Health 19(19), 12366. https:\/\/doi.org\/10.3390\/ijerph191912366\u00a0(2022).","DOI":"10.3390\/ijerph191912366"},{"key":"77210_CR4","doi-asserted-by":"publisher","first-page":"100304","DOI":"10.1016\/j.jcpo.2021.100304","volume":"30","author":"AJN Raymakers","year":"2021","unstructured":"Raymakers, A. J. N., Regier, D. A., Peacock, S. J. & Freeman, C. L. Health-related quality of life data collected in chimeric antigen receptor T-cell (CAR-T) therapy clinical trials. J. Cancer Policy. 30, 100304 (2021).","journal-title":"J. Cancer Policy"},{"key":"77210_CR5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1146\/annurev-med-010713-141500","volume":"65","author":"E Basch","year":"2014","unstructured":"Basch, E. New frontiers in patient-reported outcomes: adverse event reporting, comparative effectiveness, and quality assessment. Annu. Rev. Med. 65, 307\u2013317 (2014).","journal-title":"Annu. Rev. Med."},{"key":"77210_CR6","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11136-015-1099-z","volume":"25","author":"D Kyte","year":"2016","unstructured":"Kyte, D. et al. International Society for Quality of Life Research commentary on the draft European Medicines Agency reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies. Qual. Life Res. 25, 359\u2013362 (2016).","journal-title":"Qual. Life Res."},{"key":"77210_CR7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ejca.2008.09.032","volume":"45","author":"A Bottomley","year":"2009","unstructured":"Bottomley, A., Jones, D. & Claassens, L. Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency. Eur. J. Cancer. 45, 347\u2013353 (2009).","journal-title":"Eur. J. Cancer"},{"key":"77210_CR8","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1177\/0194599819852604","volume":"161","author":"AR Sedaghat","year":"2019","unstructured":"Sedaghat, A. R. Understanding the minimal clinically important difference (MCID) of patient-reported outcome measures. Otolaryngol. Head Neck Surg. 161, 551\u2013560 (2019).","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"77210_CR9","doi-asserted-by":"crossref","first-page":"390e391","DOI":"10.1016\/j.jtct.2021.01.003","volume":"27","author":"M Kamal","year":"2021","unstructured":"Kamal, M. et al. Patient-reported outcomes for Cancer patients with Hematological Malignancies Undergoing Chimeric Antigen Receptor T Cell Therapy: a systematic review. Transpl. Cell. Ther. 27, 390e391\u2013390e397 (2021).","journal-title":"Transpl. Cell. Ther."},{"key":"77210_CR10","doi-asserted-by":"publisher","first-page":"e802","DOI":"10.1097\/HS9.0000000000000802","volume":"6","author":"F Efficace","year":"2022","unstructured":"Efficace, F. et al. Chimeric Antigen receptor T-cell therapy in hematologic malignancies and patient-reported outcomes: a scoping review. Hemasphere. 6, e802 (2022).","journal-title":"Hemasphere"},{"key":"77210_CR11","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.recesp.2021.06.016","volume":"74","author":"MJ Page","year":"2021","unstructured":"Page, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev. Esp. Cardiol. (Engl Ed). 74, 790\u2013799 (2021).","journal-title":"Rev. Esp. Cardiol. (Engl Ed)"},{"key":"77210_CR12","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s11136-018-1798-3","volume":"27","author":"CAC Prinsen","year":"2018","unstructured":"Prinsen, C. A. C. et al. COSMIN guideline for systematic reviews of patient-reported outcome measures. Qual. Life Res. 27, 1147\u20131157 (2018).","journal-title":"Qual. Life Res."},{"key":"77210_CR13","volume-title":"H. Comprehensive Meta-Analysis Version 2","author":"M Borenstein","year":"2005","unstructured":"Borenstein, M., Higgins, H. L. & Rothstein, J. H. Comprehensive Meta-Analysis Version 2 (Engelwood, NJ, 2005)."},{"key":"77210_CR14","first-page":"63","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version","author":"J Higgins","year":"2022","unstructured":"Higgins, J., Cumpston, C. J., Li, M., Page, T., Welch, M. J. VA. Cochrane Handbook for Systematic Reviews of Interventions Version 63 (2022)."},{"key":"77210_CR15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","volume":"11","author":"TB Huedo-Medina","year":"2006","unstructured":"Huedo-Medina, T. B., Sanchez-Meca, J., Marin-Martinez, F. & Botella, J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol. Methods. 11, 193\u2013206 (2006).","journal-title":"Psychol. Methods"},{"key":"77210_CR16","first-page":"ED000142","volume":"10","author":"M Cumpston","year":"2019","unstructured":"Cumpston, M. et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst. Rev. 10, ED000142 (2019).","journal-title":"Cochrane Database Syst. Rev."},{"key":"77210_CR17","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jtct.2022.05.004","volume":"28","author":"S Sidana","year":"2022","unstructured":"Sidana, S. et al. Longitudinal patient reported outcomes with CAR-T cell therapy Versus Autologous and Allogeneic Stem Cell Transplant. Transpl. Cell. Ther. 28, 473\u2013482 (2022).","journal-title":"Transpl. Cell. Ther."},{"key":"77210_CR18","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.3324\/haematol.2021.278288","volume":"107","author":"R Ram","year":"2022","unstructured":"Ram, R. et al. Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients - a matched control multicenter cohort study. Haematologica. 107, 1111\u20131118 (2022).","journal-title":"Haematologica"},{"key":"77210_CR19","doi-asserted-by":"publisher","unstructured":"Oswald, L. B. et al. Longitudinal Collection of patient-reported outcomes and Activity Data during CAR-T therapy: feasibility, acceptability, and data visualization. Cancers (Basel)\u00a014(11), 2742. https:\/\/doi.org\/10.3390\/cancers14112742\u00a0(2022).","DOI":"10.3390\/cancers14112742"},{"key":"77210_CR20","doi-asserted-by":"publisher","first-page":"e897","DOI":"10.1016\/S2352-3026(22)00284-8","volume":"9","author":"T Martin","year":"2022","unstructured":"Martin, T. et al. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study. Lancet Haematol. 9, e897\u2013e905 (2022).","journal-title":"Lancet Haematol."},{"key":"77210_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s43856-022-00116-5","volume":"2","author":"JM Knight","year":"2022","unstructured":"Knight, J. M. et al. Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy. Commun. Med. (Lond). 2, 49 (2022).","journal-title":"Commun. Med. (Lond)"},{"key":"77210_CR22","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1182\/blood.2022015478","volume":"140","author":"M Elsawy","year":"2022","unstructured":"Elsawy, M. et al. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma. Blood. 140, 2248\u20132260 (2022).","journal-title":"Blood"},{"key":"77210_CR23","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1182\/bloodadvances.2021005913","volume":"6","author":"M Delforge","year":"2022","unstructured":"Delforge, M. et al. Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma. Blood Adv. 6, 1309\u20131318 (2022).","journal-title":"Blood Adv."},{"key":"77210_CR24","doi-asserted-by":"publisher","first-page":"5969","DOI":"10.1182\/bloodadvances.2022008106","volume":"6","author":"JS Abramson","year":"2022","unstructured":"Abramson, J. S. et al. Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL. Blood Adv. 6, 5969\u20135979 (2022).","journal-title":"Blood Adv."},{"key":"77210_CR25","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah, B. D. et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 398, 491\u2013502 (2021).","journal-title":"Lancet"},{"key":"77210_CR26","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1182\/bloodadvances.2020003503","volume":"5","author":"DL Patrick","year":"2021","unstructured":"Patrick, D. L. et al. Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed\/refractory large B-cell lymphoma. Blood Adv. 5, 2245\u20132255 (2021).","journal-title":"Blood Adv."},{"key":"77210_CR27","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1093\/neuonc\/noab077","volume":"23","author":"D Maillet","year":"2021","unstructured":"Maillet, D. et al. Evaluation of mid-term (6\u201312 months) neurotoxicity in B-cell lymphoma patients treated with CAR T cells: a prospective cohort study. Neuro Oncol. 23, 1569\u20131575 (2021).","journal-title":"Neuro Oncol."},{"key":"77210_CR28","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1002\/cam4.3664","volume":"10","author":"AI Hoogland","year":"2021","unstructured":"Hoogland, A. I. et al. Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucel. Cancer Med. 10, 1936\u20131943 (2021).","journal-title":"Cancer Med."},{"key":"77210_CR29","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang, M. et al. KTE-X19 CAR T-Cell therapy in relapsed or Refractory Mantle-Cell Lymphoma. N Engl. J. Med. 382, 1331\u20131342 (2020).","journal-title":"N Engl. J. Med."},{"key":"77210_CR30","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1182\/bloodadvances.2019001026","volume":"4","author":"RT Maziarz","year":"2020","unstructured":"Maziarz, R. T. et al. Patient-reported long-term quality of life after tisagenlecleucel in relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv. 4, 629\u2013637 (2020).","journal-title":"Blood Adv."},{"key":"77210_CR31","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/S1470-2045(19)30493-0","volume":"20","author":"TW Laetsch","year":"2019","unstructured":"Laetsch, T. W. et al. Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. Lancet Oncol. 20, 1710\u20131718 (2019).","journal-title":"Lancet Oncol."},{"key":"77210_CR32","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1182\/blood.V112.11.2376.2376","volume":"112","author":"GC Carter","year":"2008","unstructured":"Carter, G. C., Liepa, A. M., Zimmermann, A. H. & Morschhauser, F. Validation of the Functional Assessment of Cancer Therapy - Lymphoma (FACT-LYM) in patients with Relapsed\/Refractory Mantle Cell Lymphoma. Blood. 112, 828\u2013828 (2008).","journal-title":"Blood"},{"key":"77210_CR33","doi-asserted-by":"publisher","first-page":"e524","DOI":"10.1097\/HS9.0000000000000524","volume":"5","author":"R Heine","year":"2021","unstructured":"Heine, R. et al. Health Economic aspects of chimeric Antigen receptor T-cell therapies for hematological cancers: Present and Future. Hemasphere. 5, e524 (2021).","journal-title":"Hemasphere"},{"key":"77210_CR34","doi-asserted-by":"publisher","unstructured":"Ghisoni, E. et al. Patient-reported outcomes in adoptive cell-therapy trials: mind the gap. J. Immunother. Cancer 10(12), e006082. https:\/\/doi.org\/10.1136\/jitc-2022-006082\u00a0(2022).","DOI":"10.1136\/jitc-2022-006082"},{"key":"77210_CR35","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.tmrv.2019.01.005","volume":"33","author":"EJM Grigor","year":"2019","unstructured":"Grigor, E. J. M. et al. Risks and benefits of chimeric Antigen receptor T-Cell (CAR-T) therapy in Cancer: a systematic review and Meta-analysis. Transfus. Med. Rev. 33, 98\u2013110 (2019).","journal-title":"Transfus. Med. Rev."},{"key":"77210_CR36","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/EDBK_238691","volume":"39","author":"B Santomasso","year":"2019","unstructured":"Santomasso, B., Bachier, C., Westin, J., Rezvani, K. & Shpall, E. J. The other side of CAR T-Cell therapy: Cytokine Release Syndrome, neurologic toxicity, and Financial Burden. Am. Soc. Clin. Oncol. Educ. Book. 39, 433\u2013444 (2019).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"77210_CR37","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s11136-006-0050-8","volume":"15","author":"KW Wyrwich","year":"2006","unstructured":"Wyrwich, K. W. & Tardino, V. M. Understanding global transition assessments. Qual. Life Res. 15, 995\u20131004 (2006).","journal-title":"Qual. Life Res."},{"key":"77210_CR38","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/BF00439229","volume":"5","author":"MT King","year":"1996","unstructured":"King, M. T. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual. Life Res. 5, 555\u2013567 (1996).","journal-title":"Qual. Life Res."},{"key":"77210_CR39","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","volume":"16","author":"D Osoba","year":"1998","unstructured":"Osoba, D., Rodrigues, G., Myles, J., Zee, B. & Pater, J. Interpreting the significance of changes in health-related quality-of-life scores. J. Clin. Oncol. 16, 139\u2013144 (1998).","journal-title":"J. Clin. Oncol."},{"key":"77210_CR40","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s12955-020-01578-8","volume":"18","author":"X Hu","year":"2020","unstructured":"Hu, X., Jing, M., Zhang, M., Yang, P. & Yan, X. Responsiveness and minimal clinically important difference of the EQ-5D-5L in cervical intraepithelial neoplasia: a longitudinal study. Health Qual. Life Outcomes. 18, 324 (2020).","journal-title":"Health Qual. Life Outcomes"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77210-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77210-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77210-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T10:27:27Z","timestamp":1732962447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77210-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["77210"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-77210-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"assertion":[{"value":"22 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Catholic University of Korea institutional review board (IRB) determined that this study has been granted an exemption from requiring ethics approval by the IRB as this literature review did not involve the participation of human subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25752"}}